作者：
Fredrika,Hellgren [1]
;
Alberto,Cagigi [2]
;
Rodrigo,Arcoverde Cerveira [1]
;
Sebastian,Ols [1]
;
Theresa,Kern [1]
;
Ang,Lin [3]
;
Bengt,Eriksson [4]
;
Michael G,Dodds [5]
;
Edith,Jasny [6]
;
Kim,Schwendt [6]
;
Conrad,Freuling [7]
;
Thomas,Müller [7]
;
Martin,Corcoran [8]
;
Gunilla B,Karlsson Hedestam [8]
;
Benjamin,Petsch [6]
;
Karin,Loré [9]
作者单位：
Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.;Center of Molecular Medicine, Stockholm, Sweden.
[1]
Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.;Center of Molecular Medicine, Stockholm, Sweden.;Nykode Therapeutics, Oslo, Norway.
[2]
Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.;Center of Molecular Medicine, Stockholm, Sweden.;School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
[3]
Astrid Fagraeus Laboratory, Comparative Medicine, Karolinska Institutet, Stockholm, Sweden.
[4]
Certara USA, Inc, Princeton, NJ, USA.
[5]
CureVac SE, Tübingen, Germany.
[6]
Institute for Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Greifswald, Germany.
[7]
Department of Microbiology and Tumor Biology, Karolinska Institutet, Stockholm, Sweden.
[8]
Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. karin.lore@ki.se.;Center of Molecular Medicine, Stockholm, Sweden. karin.lore@ki.se.
[9]
DOI
10.1038/s41467-023-39421-5
PMID
37349310
发布时间
2024-12-07
换一批
换一批
